Bio-Path Holdings Provides Update From Phase 1/1b Trial Of BP1001-A In Solid Tumor Patients; Says First Solid Tumor Patient Treated With Second, Higher Dose In Trial Experienced Tumor Reduction And Continued Stable Disease
Portfolio Pulse from Benzinga Newsdesk
Bio-Path Holdings announced an update from its Phase 1/1b trial of BP1001-A in solid tumor patients. The first patient treated with a higher dose experienced tumor reduction and stable disease.
August 21, 2024 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bio-Path Holdings' Phase 1/1b trial of BP1001-A shows promising results with tumor reduction in a solid tumor patient treated with a higher dose.
The news of tumor reduction in a patient treated with a higher dose of BP1001-A is a positive development for Bio-Path Holdings. This could lead to increased investor confidence and a potential rise in BPTH stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100